Australia unveiled a major investment to advance brain cancer clinical research, spotlighting landmark immunotherapy breakthroughs and patient-focused innovation
Australia unveiled a major investment to advance brain cancer clinical research, spotlighting landmark immunotherapy breakthroughs and patient-focused innovation
Megafunding rounds and regulatory momentum reshaped the biotech investment landscape, signaling growing confidence in transformative clinical innovation.
Japanese pharma giant Taiho invests up to $1.14 billion in Swiss innovation, expanding its portfolio in antibody-drug conjugates …
Regeneron and Sanofi bolster their immunology-focused portfolios by acquiring global rights to a promising monoclonal antibody targeting autoimmune …
Amgen advances clinical research with promising data in cardiovascular disease and cancer, reinforcing its commitment to innovation and …
Major pharma players unveil significant clinical trial progress and strategic collaborations targeting obesity and cardiovascular health.
Recent developments underscore innovation in rare diseases and artificial intelligence, reshaping treatment paradigms and accelerating drug development.
March 2025 is marked by significant deal-making, promising clinical trial results, and innovations across small molecules, biologics, and …
India’s Sun Pharmaceutical Industries strengthens its immuno-oncology capabilities with acquisition of U.S.-based Checkpoint Therapeutics.
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
Already a subscriber? Log in